Table 4 Multivariate analysis for all ipsilateral recurrent events and for recurrence of ipsilateral invasive disease

From: A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial

 

Recurrence of all ipsilateral disease (DCIS or invasive)

Recurrence of ipsilateral invasive carcinoma

Covariate

No. cases

HR

95% CI

No. cases

HR

95% CI

New grading system

      

 Low and intermediate

310

1a

 

309

1a

 

 High

424

1.69

0.99–2.89

423

0.86

0.35–2.11

 Very high

477

2.77

1.69–4.57

476

1.46

0.65–3.31

XRT received

      

 No XRT

776

1a

 

774

1a

 

 XRT

435

0.34

0.23–0.52

434

0.52

0.27–0.98

Tumour size

      

 0–0.9 cm

368

1a

 

366

1a

 

 1.0–1.9 cm

575

1.67

1.07–2.59

574

1.89

0.89–3.99

 ⩾2 cm

268

2.67

1.66–4.30

268

1.89

0.80–4.49

Excision

      

 Complete

838

1a

 

835

1a

 

 Incomplete

192

1.47

0.98–2.22

192

1.01

0.46–2.21

 Uncertain

181

1.82

1.21–2.73

181

2.35

1.27–4.37

Inflammation

      

 Absent

   

294

1a

 

 Present

   

914

3.11

1.06–9.13

  1. Abbreviations: CI=confidence interval; DCIS=ductal carcinoma in situ; HR=hazard ratio; XRT=radiotherapy.
  2. aBaseline category.